Oklahoma Mandates Federal DEA Registration for Medical Cannabis Businesses
Oklahoma drug officials have issued guidance requiring medical marijuana businesses to register with the federal government to avoid potential state-level penalties. This directive, issued by the Oklahoma Bureau of Narcotics and Dangerous Drugs Control (OBNDD), specifies that distributors and manufacturers of medical marijuana products must obtain a federal Drug Enforcement Administration (DEA) registration.
Donnie Anderson, director of the OBNDD, communicated this requirement in a letter to cannabis industry operators, citing state laws that mandate compliance with federal regulations. The new DEA registration form was introduced following the Trump administration’s move to federally reschedule cannabis.
Compliance Requirements and Timeline
The OBNDD letter clarifies that failure to secure a DEA registration could lead to administrative sanctions, including the potential revocation of a registrant’s OBNDD registration. This aligns with existing requirements for other Schedule III registrants regulated by the OBNDD.
To facilitate compliance and minimise disruption, the OBNDD has stated it will not pursue administrative action against medical marijuana businesses for manufacturing or distributing without the required DEA registration until January 1, 2027. However, it is strongly recommended that all OBNDD registrants authorised for manufacturing or distribution apply for the appropriate DEA registration within 60 days of the April 28, 2026, publication of the Final Order.
- Timely submission of a DEA application within this 60-day period will protect registrants from OBNDD administrative action while the application is pending.
- Failure to submit an application within the specified timeframe would render any manufacturing or distribution of medical marijuana products without a DEA registration a violation of the Final Order, potentially subjecting the registrant to OBNDD administrative sanctions.
Director Anderson noted that the letter is intended solely to inform medical marijuana businesses of their administrative responsibilities and should not be construed as legal advice. Registrants with further questions are advised to consult with an attorney.
State-Level Response and Political Discourse
The Oklahoma Medical Marijuana Authority (OMMA), responsible for licensing and regulating medical cannabis businesses in the state, also released separate guidance concerning federal rescheduling and a recently filed lawsuit challenging the reform. OMMA Executive Director Adria Berry stated that the agency’s focus remains on patient health, safety, and responsible industry regulation, acknowledging the many unanswered questions arising from these federal announcements. OMMA encourages licensees to seek professional counsel to determine the best decisions for their businesses.
These regulatory adjustments occur amidst ongoing political debate within Oklahoma regarding the state’s medical cannabis program. Governor Kevin Stitt (R) suggested in his February State of the State address that lawmakers should propose a ballot measure to roll back the program. He argued that voters were misled by proponents of the initial ballot initiative, a sentiment he also expressed in 2022. However, legislative leaders have largely resisted this idea.
- Senate President Pro Tempore Lonnie Paxton (R) acknowledged the difficulty of undoing the program, citing the investments made by licensed medical cannabis operators.
- House Speaker Kyle Hilbert (R) has also dismissed the prospect of dismantling the program, noting Oklahomans’ clear distinction between support for medical marijuana and opposition to adult-use legalisation, based on past election results.
Despite legislative pushback, Governor Stitt has indicated ongoing discussions with the House and Senate, claiming public concern about the program. Separately, Oklahoma Attorney General Gentner Drummond (R) expressed a desire to see the medical marijuana program eliminated but cautioned that such a move would necessitate reimbursing hundreds of licensees for their lost revenue sources. In November, activists withdrew an adult-use marijuana legalisation initiative that they had intended to place on the state’s 2026 ballot, as previously reported by Hemp Gazette.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
